ABSTRACT
Purpose We determined whether a large, multi-analyte panel of circulating biomarkers can improve detection of early-stage pancreatic ductal adenocarcinoma (PDAC).
Experimental Design We defined a biologically relevant subspace of blood analytes based on previous identification in premalignant lesions or early-stage PDAC and evaluated each in pilot studies. The 31 analytes that met minimum diagnostic accuracy were measured in serum of 837 subjects (461 healthy, 194 benign pancreatic disease, 182 early stage PDAC). We used machine learning to develop classification algorithms using the relationship between subjects based on their changes across the predictors. Model performance was subsequently evaluated in an independent validation data set from 186 additional subjects.
Results A classification model was trained on 669 subjects (358 healthy, 159 benign, 152 early-stage PDAC). Model evaluation on a hold-out test set of 168 subjects (103 healthy, 35 benign, 30 early-stage PDAC) yielded an area under the receiver operating characteristic (ROC) curve (AUC) of 0.920 for classification of PDAC from non-PDAC (benign and healthy controls) and an AUC of 0.944 for PDAC vs. healthy controls. The algorithm was then validated in 146 subsequent cases presenting with pancreatic disease (73 benign pancreatic disease, 73 early and late stage PDAC) as well as 40 healthy control subjects. The validation set yielded an AUC of 0.919 for classification of PDAC from non-PDAC and an AUC of 0.925 for PDAC vs. healthy controls.
Conclusions Individually weak serum biomarkers can be combined into a strong classification algorithm to develop a blood test to identify patients who may benefit from further testing.
Competing Interest Statement
MAF and SJM are inventors named on a patent held by the University of Utah for claims associated with this project. MCT, AR, VDL, LM, MDM and AF are shareholders of BIOUNIVERSA s.r.l. that is involved in the development of BAG3 specific diagnostic reagents. MCT is inventor of a patent in the field of BAG3 used as a biomarker in the diagnosis of pancreatic cancer. The other authors declare no potential conflicts of interest.
Funding Statement
This study was partially supported by research grants from the National Institutes of Health to SJM and to the Huntsman Cancer Institute for support of core facilities, grants from the Huntsman Cancer Institute Gastrointestinal Cancer Research Program and through support from the Huntsman Cancer Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the University of Utah gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This study was partially supported by research grants from the National Institutes of Health (CA115225, CA151650, CA155586, CA196403, CA200468 to SJM and P30CA042014 to the Huntsman Cancer Institute for support of core facilities), grants from the Huntsman Cancer Institute Gastrointestinal Cancer Research Program and through support from the Huntsman Cancer Foundation (MAF, SJM).
MAF and SJM are inventors named on a patent held by the University of Utah for claims associated with this project. MCT, AR, VDL, LM, MDM and AF are shareholders of BIOUNIVERSA s.r.l. that is involved in the development of BAG3 specific diagnostic reagents. MCT is inventor of a patent in the field of BAG3 used as a biomarker in the diagnosis of pancreatic cancer. The other authors declare no potential conflicts of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
